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Abstract
Over the past 10 years, the number of percutaneous coronary intervention procedures performed in the United
States increased by 33%; however, restenosis, which inhibits complete functional recovery of the vessel wall,
complicates this procedure. A wide range of anti-restenotic therapeutics have been developed, although many elicit
non-specific effects that compromise vessel healing. Drawing inspiration from biologically-relevant molecules, our lab
developed a mimic of the natural proteoglycan decorin, termed DS-SILY, which can mask exposed collagen and
thereby effectively decrease platelet activation, thus contributing to suppression of vascular intimal hyperplasia. Here,
we characterize the effects of DS-SILY on both proliferative and quiescent human SMCs to evaluate the potential
impact of DS-SILY-SMC interaction on restenosis, and further characterize in vivo platelet interactions. DS-SILY
decreased proliferative SMC proliferation and pro-inflammatory cytokine secretion in vitro in a concentration
dependent manner as compared to untreated controls. The addition of DS-SILY to in vitro SMC cultures decreased
SMC migration and protein synthesis by 95% and 37%, respectively. Furthermore, DS-SILY decreased platelet
activation, as well as reduced neointimal hyperplasia by 60%, in vivo using Ossabaw swine. These results indicate
that DS-SILY demonstrates multiple biological activities that may all synergistically contribute to an improved
treatment paradigm for balloon angioplasty.
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Introduction
Percutaneous coronary intervention (PCI) is an invasive
cardiovascular procedure performed to mechanically widen
narrowed coronary vessels using either balloon angioplasty or
intracoronary stenting. While the number of PCI procedures
performed in the United States has increased by 33% in the
past 10 years[1-3], thrombosis, neointimal hyperplasia, and
restenosis remain complications of this procedure. The
occurrence of these detrimental consequences following PCI is
attributed to trauma during the procedure, which triggers an
array of mechanical and biological processes implicated in the
healing process.
PCI often damages the endothelial cells (EC) from the vessel
wall, exposing the underlying collagenous layer and providing
inherent targets for platelet activation[4,5]. In addition, the
injured endothelium produces a plethora of pro-inflammatory
and mitogenic substances, all of which leads to the recruitment
of inflammatory cells to the site of injury, via surface expression
of adhesion molecules, and ultimately the production of a range
of pro-inflammatory factors[6-8]. Vascular smooth muscle cells
(SMC) remain targets for many of the pro-inflammatory factors
released from activated inflammatory cells and platelets[9,10].
As such, activated SMCs are stimulated to proliferate and
migrate into the neointimal layer of the vessel wall, as well as
synthesize new extracellular matrix[10-14]. Moreover,
stimulated SMCs actively participate in the inflammatory
cascade, producing and secreting a range of factors, including
interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis
factor-α (TNF-α)[9,10].
Advances within the pharmaceutical and scientific
communities have enabled medical researchers to develop a
wide range of anti-restenotic therapeutics. The overall goal of
the developed therapies is to target the key processes involved
in the healing response leading to restenosis, including platelet
activation, inflammation, SMC proliferation and migration, and
extracellular matrix synthesis[15,16]. An overwhelming number
of these therapeutics, including both paclitaxel and sirolimus
PLOS ONE | www.plosone.org 1 November 2013 | Volume 8 | Issue 11 | e82456
analogs that are widely used on drug-eluting stents, have been
shown to effectively target and inhibit SMC proliferation[17-19].
However, these compounds are non-selective cytotoxins and
as such, the effects of the compounds are not limited purely to
SMCs, but also to ECs[17]. The non-specific effects of these
therapeutics inhibit EC proliferation and migration[18,19], which
have been associated with incomplete vessel healing in
vivo[20].
In an effort to create alternative means of treating restenosis,
several research groups have investigated the use of
biologically-relevant molecules for anti-restenotic treatment,
turning to natural molecules prevalent in the native vessel wall.
One such molecule is decorin, a small proteoglycan consisting
of a single glycosaminoglycan (GAG) side chain linked to a
core protein, which accounts for approximately 22% of the
proteoglycans found in the vessel wall[21,22]. Decorin plays a
significant role in the regulation of cell migration[23-26],
proliferation[23,27], and attachment[25,26,28]. The addition of
decorin in both in vitro and in vivo studies examining restenotic
treatment has resulted in decreased SMC proliferation, SMC
migration, and collagen synthesis, but exhibited no effect on
EC proliferation and migration[23,25]. Furthermore, 10 weeks
after PCI, inflammatory cells were almost completely absent
from vessels treated with decorin[23]. However, as decorin is
relatively expensive and can be readily degraded due to its
natural presence in the body, some limitations exist for use of
this molecule in clinical applications.
Our lab synthesized a mimic of the proteoglycan
decorin[29,30]. This mimic, termed DS-SILY, consists of type-I
collagen-binding peptides bound to a dermatan sulfate (DS)
backbone. This anti-thrombotic biomolecule has been shown to
specifically bind to type-I collagen, serving as a barrier to
platelet adhesion and activation in vitro[30]. Furthermore, DS-
SILY stimulated EC migration on collagen-coated substrates
and delivery of this decorin mimic from porous balloons in
porcine vessels resulted in significantly decreased arterial
vasospasm compared to vessels treated with saline
solution[30].
As treatment of SMCs with decorin has previously
demonstrated inhibition of SMC proliferation and migration, we
further characterized the effects of our decorin mimic, DS-SILY,
on the anti-restenotic properties of SMCs. We demonstrate
here the use of this antithrombotic biomolecule to control SMC
migration, protein synthesis, cytokine excretion, and vascular
injury marker production of both proliferative and quiescent
SMCs in vitro. Furthermore, we examine the effects of this
molecule on platelet adhesion and activation in vivo, as well as
on intimal hyperplasia in Ossabaw swine.
Materials and Methods
DS-SILY20 Synthesis
The decorin mimic (DS-SILY) was synthesized as previously
described[30]. Briefly, carboxyl groups present on the
backbone of dermatan sulfate (DS, MW 46,275 Da, Celsus
Laboratories) were oxidized via standard periodate oxidation to
form aldehyde moieties. Oxidized DS was then covalently
coupled to the heterobifunctional crosslinker N-[b-
maleimidopropionic acid] hydrazide, trifluoroacetic acid salt
(BMPH, Thermo Fisher Scientific) in phosphate buffered saline
(PBS). The collagen-binding peptide sequence
RRANAALKAGELYKSILYGC (noted as SILY, Genscript),
derived from the platelet receptor to type I collagen, was
conjugated to the DS-BMPH compound; specifically, the thiol
group on the cysteine amino acid reacted with the maleimide
group of BMPH to form a thioether bond. Purifications were
performed at each step by size exclusion chromatography and
the number of attached peptides was determined by the
consumption of BMPH in the second reaction step. The final
product DS-SILYn, where n indicates the number of attached
SILY peptides, was purified in ultrapure H2O, lyophilized and
stored at -20°C until use.
Cell Culture
Human coronary artery smooth muscle cells (SMC,
Invitrogen) were cultured in Media 231 (M231, Invitrogen),
supplemented with 4.9% fetal bovine serum (FBS, Invitrogen),
2 ng/mL basic fibroblast growth factor (Invitrogen), 0.5%
epidermal growth factor (Invitrogen), 5 ng/mL heparin
(Invitrogen), 5 μg/mL insulin (Invitrogen), and 0.2 μg/mL bovine
serum albumin (BSA, Invitrogen). Unless otherwise noted, cells
were initially seeded at 5x104 cells/cm2 in Ibidi angiogenesis μ-
slide (Ibidi) and allowed to proliferate for 24 hrs to allow the
formation of multilayered cell constructs. Media was removed
and cultures were treated either with proliferative media, as
described above, or contractile media to induce a quiescent
phenotype, for 24 hrs. Previously, we have demonstrated that
the addition of contractile media, consisting of M231
supplemented with 1% FBS and 30 μg/mL heparin, induced
SMCs to transition from a proliferative state to a more
differentiated, contractile state due to low serum and
introduction of heparin[31]. Treatments were applied to the
SMC cultures using co-culture media, which was composed of
Media 200 (M200, Invitrogen) with 2% FBS, 1 μg/mL
hydrocortisone (Invitrogen), 30 ng/mL heparin, and 0.2 μg/mL
BSA. Cells were used between passage numbers 3 and 8 for
all assays and maintained at 37°C with 5% CO2.
SMC Metabolic Activity and Proliferation
Cells were incubated in the presence of 0, 0.01, 0.1, 1, or 10
μM DS-SILY20 for 24 hrs. The metabolic activity of the cells was
determined using the CellTiter 96 AQueous One Solution Cell
Proliferation Assay (Promega). Briefly, media was mixed with
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt (MTS) and cultures were
re-incubated for 2 hrs at 37°C with 5% CO2. The media
containing MTS was then transferred into a 96-well plate and
absorbance at 490 nm was measured.
The effect of DS-SILY20 on cell proliferation was assessed by
determining the number of cells per volume after treatment.
Cultures were fixed with 4% formaldehyde and nuclei were
stained using SYTOX green (Invitrogen). Cells were visualized
using an Olympus FV1000 confocal microscope with 60x
objective. Scans were completed with a xy area of 512 μm2 and
one stack, 14 μm (1 μm per step) in the z-direction, was taken
at three separate locations in each culture. Cell nuclei were
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counted, such that cell proliferation was assessed by
determining the number of SMC nuclei per volume.
Migration
SMC migration was examined via a modified Boyden
chamber, using a polycarbonate filter (8.0 μm pore size,
Corning) to divide the upper and lower chambers. The lower
chamber of each well was filled with serum-free M200
containing 1% BSA. SMCs were trypsinized and resuspended
in serum-free M200 containing 1% BSA with or without varying
concentrations of DS-SILY20. Cells (5x104 cells/cm2) were
added to the upper portion of the transwell chamber and
incubated for 5 hrs at 37°C. Following incubation, cells were
fixed in 4% formaldehyde and nuclei stained with Hoechst
33342. Transwells were then mounted on glass slides and
migratory SMCs visible on the lower side of the filters were
counted by light microscopy using 10x magnification.
Protein Synthesis
Cells were incubated in the presence of 0, 0.01, 0.1, 1, or 10
μM DS-SILY20 for 24 hrs. Cells were washed twice with ice cold
PBS, scraped in lysis buffer (9 M urea, 4% CHAPS, and
phosphatase inhibitor cocktail-1 (Sigma) in Millipore water),
and frozen overnight at -80°C. Lysates were processed for 3
hrs in a Disruptor Genie (Scientific Industries) at 4°C and
centrifuged for 20 min at 18,000×g to remove membrane
components. A BCA assay protein kit (Pierce) was used to
quantify total protein.
To determine the effects of DS-SILY20 on protein synthesis in
both proliferative and differentiated SMC cultures, click
chemistry was utilized to fluorescently label newly synthesized
proteins (Figure S1)[32]. After washing the cells once with
PBS, cells were incubated at 37°C for 60 min with serum-free
media to deplete methionine reserves. Cultures were then
supplemented with 1 μM L-azidohomoalanine (AHA, Invitrogen)
in serum-free media for 4 hrs. Cells were then rinsed with PBS
to remove any excess AHA and incubated with co-culture
media overnight to allow protein production. Cultures were
fixed with 4% formaldehyde, permeabilized with 0.25% Triton
X-100 in PBS, and blocked with 1% BSA in PBS. To detect the
newly synthesized proteins containing AHA, alkyne-labeled
Alexa Fluor 594 (AF-594, Invitrogen) was selectively bound via
copper-catalyzed azide-alkyne ligation. Cell nuclei were stained
using SYTOX green.
Proteins were visualized using an Olympus FV1000 confocal
microscope with 60x objective. Scans were completed with a
xy area of 512 μm2 and one stack, 14 μm (1 μm per step) in the
z-direction, was taken at three separate locations in each
culture. Each stack was taken at the same exposure settings to
ensure similar darkness values; cultures lacking AHA-treatment
were utilized as controls. ImageJ was used to determine the
average fluorescent intensity of each stack based on AF-594
fluorescence. Average fluorescent intensity of each stack was
then normalized to the number of cells in the 3D image.
Effect of DS-SILY20 on SMC Cytokine Production
Cells were incubated in the presence of 0, 0.01, 0.1, 1, or 10
μM DS-SILY20 for 24 hrs. Media was removed from the cultures
and a Pro-Inflammatory I kit (Meso Scale Discovery) was used
to analyze cytokine production of SMCs according to
manufacturer’s instructions. Briefly, plates were warmed to
room temperature and incubated with 25 μL of samples and
standards for 2 hours at room temperature with vigorous
shaking. The detection antibody was then added to the plate
and incubated for 2 hours at room temperature with vigorous
shaking. After washing three times with PBS with 0.05%
Tween-20, 2X read buffer was added to the plate and imaged
using a Sector Imager 2400A (Meso Scale Discovery). The
pro-inflammatory markers interferon-γ (IFN-γ), interleukin-1β
(IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-
α) were examined in this study. Data were analyzed using the
MSD Discovery Workbench Software.
Effect of DS-SILY20 on SMC Thrombomodulin
Production
Following treatment with 0, 0.01, 0.1, 1, or 10 μM DS-SILY20
for 24 hrs, cells were washed twice with ice cold PBS, scraped
in lysis buffer (9 M urea, 4% CHAPS, and phosphatase
inhibitor cocktail-1 in Millipore water), and frozen overnight at
-80 °C. Lysates were processed for 3 hrs in a Disruptor Genie
(Scientific Industries) at 4°C and centrifuged for 20 min at
18,000×g to remove membrane components. A BCA assay
protein kit (Pierce) was used to quantify total protein. A
Vascular Injury Marker I kit (Meso Scale Discovery) was used
to analyze thrombomodulin production of SMCs according to
manufacturer’s instructions. Briefly, plates were warmed to
room temperature and incubated with 10 μL of samples and
standards for 2 hrs at room temperature with vigorous shaking.
Following gentle rinsing of the wells, the detection antibody
was then added and incubated for 1 hr at room temperature
with vigorous shaking. After washing three times with PBS with
0.05% Tween-20, 2X Read buffer was added to the plate and
imaged using a Sector Imager 2400A. Data were analyzed
using the MSD Discovery Workbench Software.
Effect of DS-SILY20 on Platelet Deposition and
Hyperplasia In Vivo
An Ossabaw pig angioplasty model was used to assess
platelet deposition (acute) and neointimal hyperplasia (1-month
recovery) after DS-SILY20 treatment. Ossabaw pigs under-went
angioplasty procedures following approved protocols at the
Indiana University School of Medicine similar to previous
methods described in detail[33-35]. Each animal received pre-
anesthesia with intramuscular injections of xylazine (2.2 mg/kg)
and telazol (6.6 mg/kg). Following intubation, isoflurane (2-4%,
with oxygen) was administered to maintain stable systemic
hemodynamics and a stable level of anesthesia. Under sterile
conditions, the right carotid artery was exposed with surgical
cut-down technique and an 8F vascular introducer sheath was
inserted into the carotid artery followed by administration of
heparin (200 Units/kg). An 8F Amplatz left, or other appropriate
guiding catheter (Cordis Corporation), was inserted through the
sheath and advanced near the target site.
Porous angioplasty balloons (Cook Medical, Bloomington,
IN) were employed for delivery of soluble DS-SILY20 to the
target arteries in the peripheral vasculature of the pigs. Renal,
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femoral, and iliac arteries were denuded by balloon expansion
and movement in the artery, followed by delivery of the
therapeutic through the porous balloon. Treatment consisted of
2 mL of 10 μM DS-SILY20 dissolved in saline; saline alone was
delivered as a sham control. In some cases, bare-metal stents
were placed such that they partially overlapped the 20 mm
treated artery segment. Stent placement was used as a marker
for harvesting treated arteries, and to assess the healing
response with stent placement. For each treatment group, 3
animals were utilized.
Arteries for assessing the acute response of balloon injury
were harvested within hours of angioplasty. The artery
segments were rinsed with saline and fixed in 10% formalin
overnight, followed by ethanol dehydration. Arteries were then
critical point dried, sputter coated with platinum, and visualized
by scanning electron microscopy (SEM).
Neointimal hyperplasia was assessed by histology after a 1-
month recovery. In arteries where stents partially overlapped
the treated segment, a gap of several millimeters between the
stent and stent-free segment was removed from analysis to
avoid stent edge effects. Neointimal hyperplasia was analyzed
by measuring the distance from either the internal elastic
lamina or a stent post to the lumen in stent-free or stented
artery segments, respectively. In two cases, stents were
crushed due to placement near a joint, and were excluded from
analysis.
Statistical Analysis
Results are expressed as means ± standard error. Statistical
analysis was performed using SAS software (SAS Institute). All
results were analyzed using ANOVA with Tukey HSD post-hoc
test. The threshold for statistical significance was set at p<0.05.
Results
SMC Metabolic Activity
To better understand the effects of DS-SILY on SMC
behavior, SMCs cultures eliciting either a proliferative or
quiescent phenotype were utilized. Quiescent SMC cultures
were generated in vitro by reducing serum concentrations and
adding heparin to SMC media, as previously demonstrated[31].
Using the CellTiter 96 AQueous One Solution Cell Proliferation
Assay, no change in SMC metabolic activity was exhibited with
the addition of any concentration of DS-SILY20 (data not
shown). This general trend was demonstrated by both the
proliferative and quiescent cultures, as compared to controls.
Proliferation
Proliferation of SMCs was assessed by determining the
number of SMC nuclei per cell culture volume following the
culture period. Significantly increased numbers of SMC cells
were found in proliferative cultures compared to quiescent
cultures (Figure 1A & B). For proliferative SMC cultures, the
addition of DS-SILY20 resulted in decreased proliferation
compared to controls, where a significant reduction of SMC
proliferation occurred with treatments of 0.1, 1, and 10 μM DS-
SILY20. While DS-SILY20 elicited a response from proliferative
cultures, no change in proliferation was exhibited in quiescent
SMC cultures.
Migration
SMC migration was examined using a modified Boyden
chamber[36]. Significantly increased migration was exhibited
by SMCs in a proliferative phenotype compared to SMCs in a
contractile phenotype (Figure 1C & D). The effect of DS-SILY20
on SMC migration was examined; a general trend was
observed such that as the amount of DS-SILY20 increased,
SMC migration decreased in both proliferative and quiescent
cultures. For proliferative SMCs, a significant decrease in
migration was observed for all concentrations of DS-SILY20
tested, ultimately culminating with a ~95% decrease in
migratory cells in cultures treated 10 μM DS-SILY20 compared
to controls. The addition of 0.1 and 1 μM DS-SILY20 to
proliferative cultures decreased migration to a level similar to
that of quiescent cells; while treatment of proliferative SMCs
with 10 μM DS-SILY20 resulted in significantly decreased
migration compared to quiescent controls. A significant
decrease in the number of migratory cells was only observed in
quiescent cultures treated with 1 or 10 μM DS-SILY20.
Protein synthesis
Total protein in cultures was assessed via microBCA assay
compared to the number of cells per culture, as assessed in
proliferation experiments. In proliferative cultures, SMCs
produced 3.5 ± 0.3 ng of protein per cell, while only 2.2 ± 0.4
ng of protein per cell was produced by quiescent SMCs. De
novo protein synthesis following DS-SILY20 treatment, and
doping with AHA, was analyzed by detecting the presence of
the incorporated AHA within proteins via click chemistry
reaction, which attached a fluorescent tag directly to the
unnatural amino acid. By quantification of fluorescent intensity,
proliferative SMC cultures were found to synthesize
approximately 65% more protein compared to quiescent
cultures (Figure 2). In proliferative SMC cultures, a significant
decrease in protein expression was observed in cultures
treated with 10 μM DS-SILY20, where approximately 37% less
protein was synthesized compared to control proliferative
cultures. Lower concentrations of DS-SILY20 did not elicit a
change in protein synthesis in proliferative cultures. Likewise,
protein synthesis in quiescent cultures was not altered with the
addition of any concentration DS-SILY20.
Cytokine Expression
Expression of IFN-γ, IL-1β, IL-6, and TNF-α from SMC
cultures was examined via MSD Sector Imager. Examination of
control, non-treated cultures revealed that proliferative SMCs
exhibited increased levels of IL-1β and TNF-α compared to
quiescent cultures; however, the two cultures produced similar
levels of IFN-γ and IL-6 (Figure 3). The effect of DS-SILY20 on
the production of the four pro-inflammatory cytokines was
evaluated in both proliferative and quiescent SMC cultures. For
proliferative SMC cultures, a general trend was observed such
that as the concentration of DS-SILY20 increased, cytokine
production decreased. Significant reductions in IFN-γ, IL-6, and
TNF-α expression were exhibited with 10 μM DS-SILY20
Decorin Mimic Effects on SMC Function
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Figure 1.  Proliferation and Migration.  Proliferation (A, B) and migration (C, D) of proliferative (A, C) and quiescent (B, D) SMCs
in response to treatment with DS-SILY20. Proliferation and migration of proliferative SMCs significantly decreased with increased
concentrations of DS-SILY20. Proliferation in quiescent SMC cultures was not altered with addition of DS-SILY20 at any
concentration; however, quiescent SMC migration decreased with the addition of 1 and 10 μM DS-SILY20. * represents significance
from control non-treated cells. (N>6).
doi: 10.1371/journal.pone.0082456.g001
Figure 2.  Protein Synthesis.  Protein expression of (A) proliferative and (B) quiescent SMCs in response to treatment with DS-
SILY20. A significant decrease in protein expression was observed in proliferative SMC cultures treated with 10 μM DS-SILY20, while
no changes in protein synthesis was exhibited in proliferative SMC cultures treated with lower concentrations of DS-SILY20 or
quiescent cultures with the addition of any concentration DS-SILY20. * represents significance from control non-treated cells. (N>6).
doi: 10.1371/journal.pone.0082456.g002
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 treatment, while a significant decrease in IL-1β production was
achieved using both 1 and 10 μM DS-SILY20. A similar trend
was observed in quiescent SMC cultures with respect to IFN-γ
production, where expression of the cytokine decreased as the
concentration of DS-SILY20 increased; IFN-γin cultures treated
with 10 μM DS-SILY20 decreased by ~41% compared to
controls. The addition of 0.1, 1, and 10 μM DS-SILY20 to
quiescent SMC cultures also resulted in significantly decreased
TNF-αexpression. Interestingly, IL-1β and IL-6 production in
cultures treated with 1 or 10 μM DS-SILY20 were not different
from controls. However, an increase in IL-1β and IL-6
production occurred in quiescent cultures that were exposed to
low concentrations of DS-SILY20.
Thrombomodulin Expression
Thrombomodulin produced by SMCs in culture was analyzed
via MSD Sector Imager. Control non-treated proliferative SMCs
cultures exhibited significantly increased amounts of
thrombomodulin compared to quiescent SMC cultures (Figure
4). The addition of 0.01 μM DS-SILY20 to proliferative cultures
was found to decrease thrombomodulin expression by
approximately 60% compared to control cultures. However, as
the concentration of DS-SILY20 increased, thrombomodulin
expression in proliferative SMCs also increased. At the highest
concentrations of DS-SILY20 tested, thrombomodulin
production was approximately 25% greater compared to non-
treated proliferative cultures. Unlike proliferative SMCs, the
addition of DS-SILY20 at any concentration did not alter
thrombomodulin production in quiescent SMCs.
Analysis of Platelet Deposition and Activation on
Balloon Injured Arteries
Three Ossabaw miniature pigs underwent angioplasty
procedures and DS-SILY20 was delivered locally to
endothelium-denuded arteries through a porous PTFE balloon
catheter. To assess the acute response to balloon injury,
platelet deposition on arteries was visualized via scanning
electron microscopy. Platelets were scarcely visible on
denuded arteries treated with DS-SILY20, compared to
significant platelet coverage of the artery wall in saline-treated
arteries (Figure 5A & B). At high magnification of the vessel
walls, platelets attached on saline-treated arteries show
numerous projections and spreading of platelets in addition to
nascent fibrin strands, indicating platelet activation and early
thrombus formation (Figure 5C). However, the few platelets
seen on DS-SILY20 treated artery walls maintain a largely
rounded morphology signifying inhibition of platelet activation
(Figure 5D). Additional evidence for effective balloon
denudation of the endothelium was the completely abolished
endothelium-dependent relaxation to bradykinin (data not
shown).
Analysis of Neointimal Hyperplasia at 1-Month
Recovery
Neointimal hyperplasia was assessed by histology after 1-
month recovery in endothelium-denuded arteries treated with
10 μM DS-SILY20 or saline. Neointimal hyperplasia is observed
with and without stents in sham controls, whereas minimal
hyperplasia is observed in DS-SILY treated arteries (Figure 6A-
D). A significant reduction in neointimal hyperplasia with DS-
SILY20 treatment was observed, compared with saline sham
controls, for both stented and non-stented artery segments
(Figure 6E).
Discussion
A detrimental consequence following PCI is injury to the
vessel wall during balloon expansion, which triggers an array of
mechanical and biological processes, leading to the occurrence
of thrombosis, neointimal hyperplasia, and restenosis[37].
While many different cell types and processes are involved in
the healing response of the injured vessel, previous studies
have shown that SMC activation and extracellular matrix
deposition play important roles in intimal hyperplasia after
balloon injury[11-13]. We demonstrate here the use of an
antithrombotic biomolecule, termed DS-SILY, to control SMC
proliferation, migration, protein synthesis, cytokine excretion,
and vascular injury marker production of both proliferative and
quiescent SMCs in vitro. No measurable changes in metabolic
activity were observed in either proliferative or quiescent SMC
cultures following treatment with DS-SILY20. Furthermore, we
examined the effects of this molecule on platelet adhesion and
activation in vivo, as well as on intimal hyperplasia using an
Ossabaw pig model.
Following balloon injury, SMCs become active, proliferating
and migrating into the intima of the blood vessel wall, as well
as secreting ECM proteins and cytokines. Thus, to best
characterize the effects of our therapeutic, DS-SILY, we
examined its efficacy on both proliferative and quiescent SMC
cultures. Proliferative SMCs demonstrated increased
proliferation and motility compared to quiescent SMCs. The
addition of DS-SILY20 to cultures caused a dose dependent
decrease of SMC proliferation for proliferative cultures.
Previous reports examining SMC behavior in response to
decorin treatment indicated decreased DNA synthesis in SMCs
in vitro with the addition of decorin, similar to the results
exhibited in this study[23]. While DS-SILY20 elicited a
measurable response in proliferative cultures, no change in
proliferation was observed in quiescent cultures treated with
any concentration of DS-SILY20. This result is not unexpected
as quiescent SMCs are already in a low proliferative state.
In this study, a dose-dependent decrease of SMC migration
was observed for both proliferative and quiescent SMC
cultures, where at 10 μM DS-SILY20 SMC migration was
reduced by 95% and 47% for proliferative and quiescent
cultures, respectively, compared to controls. Previous
investigations of SMC migration in response to decorin
treatment indicate a similar phenomenon, where the addition of
decorin to in vitro cultures decreased SMC migration compared
to non-treated controls[23]. While decreased migration in this
previous work could be attributed to either the protein core or
the DS glycosaminoglycan side chain, or a synergistic effect of
both components, we demonstrate here that the DS
glycosaminoglycan plays a significant role in determining the
mobility of SMCs. This phenomenon has also been reported
previously, where SMCs cultured with exogenous DS exhibited
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Figure 3.  Cytokine Production.  Cytokine produced (A, C, E, G) proliferative and (B, D, F, H) quiescent SMCs in response to DS-
SILY20. The amount of (A, B) IFN-γ, (C, D) IL-1β, (E, F) IL-6, and (G, H) TNF-α produced by cultured SMCs was measured 24 hrs
post-treatment. For proliferative SMC cultures, a general trend was observed such that as the concentration of DS-SILY20 increased,
cytokine production decreased. Significant reductions in IFN-γand TNF-α were also observed in quiescent SMC cultures with the
addition of DS-SILY20. * represents significance from control non-treated cells. (Nγ6).
doi: 10.1371/journal.pone.0082456.g003
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a 25% reduction in SMC migration[38]. While it is not known
exactly why DS-SILY20 exhibited a larger anti-migratory effect
compared to previous work with exogenous DS, it is speculated
that the difference in the physical presentation of the molecules
to cells, exogenous compared to collagen-bound, may play a
role.
SMC migration into the intimal layer of the vessel following
vessel injury is generally accompanied by increased protein
synthesis from the activated cells[39]. Thus, as activated SMCs
express increased protein compared to SMCs found in healthy
vessel walls, the ability to control protein synthesis is also
important. As expected, protein synthesis, as detected by
fluorescently labeling newly synthesized proteins, was
significantly increased in proliferative SMC cultures compared
to quiescent cells. This is consistent with the finding that
proliferative cultures contained ~60% more protein per cell than
quiescent cultures. The addition of DS-SILY20 to cultures did
not alter protein synthesis occurring in quiescent SMCs
compared to controls; this indicates that the therapeutic likely
does not disrupt important cellular processes associated with
quiescent cell function. When applied to proliferative cultures, a
significant decrease in protein expression was achieved with
10 μM DS-SILY20, compared to non-treatment controls. The
ability of DS-SILY to suppress protein synthesis in proliferative
smooth muscle cells may contribute to less protein deposition
in the vascular wall when DS-SILY is applied to the vessel
following balloon angioplasty. Interestingly, SMCs treated with
decorin have demonstrated similar results, where SMC
collagen synthesis decreased with the addition of decorin to
cultures[23]. In addition, treatment with DS alone has been
shown to decrease collagen production in other types of
tissues, including obstructed kidney tissue[40].
While treatment with 10 μM DS-SILY20 significantly reduced
protein synthesis compared to non-treated proliferative
cultures, the reduction in protein synthesis remained
significantly increased compared to levels exhibited by
quiescent SMC cultures. Furthermore, no significant changes
in the amount of protein synthesized from proliferative cultures
treated with lower concentrations of DS-SILY20 was observed
compared to non-treated controls. Taken together, these
results indicate that increased concentrations of DS-SILY20
Figure 5.  Platelet Deposition and Activation.  SEM images
of acute platelet response on artery wall in vessels treated with
(A, C) DS-SILY20 and (B, D) sham saline control. Saline-treated
arteries exhibited significant platelet coverage with numerous
projections extending from activated platelets; platelets were
scarcely visible on denuded arteries treated with DS-SILY20.
Arrowheads indicate areas of platelet coverage. Magnification
= 3,500x (A, B); 35,000x (C, D). Scale bar = 20 μm (A, B); 2
μm (C, D).
doi: 10.1371/journal.pone.0082456.g005
Figure 4.  Thrombomodulin Production.  Thrombomodulin expression from (A) proliferative and (B) quiescent SMCs in response
to treatment with DS-SILY20. Thrombomodulin expression decreased with the addition low concentrations of DS-SILY20; however,
the addition of either 1 or 10 μM DS-SILY20 resulted in significantly increased thrombomodulin production. Thrombomodulin
production was not altered with the addition of DS-SILY20 in quiescent SMC cultures. * represents significant increase from control
non-treated cells; # represents significant decrease from control non-treated cells. (N>4).
doi: 10.1371/journal.pone.0082456.g004
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 may need to be utilized in order to decrease the amount of
protein produced by proliferative SMCs to levels similar to that
of quiescent cells. Further exploration into this phenomenon
will need to be conducted.
Following vessel injury, stimulated SMCs actively participate
in the inflammatory cycle by producing and secreting a range of
pro-inflammatory factors[41]. It has previously been
demonstrated that cytokine secreting cells are more likely to be
actively proliferating cells involved in intimal hyperplasia[41]. In
this study, proliferative SMCs expressed more TNF-α and IL-1β
than quiescent cells; however, both IFN-γ and IL-6 remained
similar between cultures. Thus, findings from this study indicate
that the transition between SMC phenotypes only affects the
production of certain cytokines, while the expression of others
remains unaltered. As such, reducing the expression of the
inflammatory cytokines directly involved in the onset of intimal
hyperplasia, in part by decreasing the participation of SMCs in
Figure 6.  Neointimal Hyperplasia.  Representative histology sections of (A, B) arteries with stents and (C, D) arteries without
stents treated with (A, C) saline or (B, D) 10 μM DS-SILY20. Arrowheads indicate location of some stent struts; internal elastic lamina
(dotted line) and lumenal border (solid line) are identified, indicating the boundaries of the neointima formed following injury. (E)
Neointimal hyperplasia was quantified by measuring the distance from a stent strut or the elastic lamina to the vessel lumen in
arteries with or without stents, respectively. A significant reduction in neointimal hyperplasia with DS-SILY20 treatment was
observed, compared with saline sham controls, for both stented and non-stented artery segments. Six measurements were taken
for each artery. Analysis with stents: sham (n=4), DS-SILY20 (n=3); without stents: sham (n=8), DS-SILY20 (n=5). Scale bar = 1 mm.*
represents significance from sham-treated vessels.
doi: 10.1371/journal.pone.0082456.g006
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the inflammatory progression that occurs following PCI, may
help minimize the restenotic cascade[42].
One of the key findings in this study is the ability of DS-
SILY20 to reduce the production of pro-inflammatory cytokines
elicited from SMCs. The addition of 10 μM DS-SILY20 to
proliferative cultures decreased the production of all four
inflammatory cytokines investigated in this work. In quiescent
cultures, the addition of high concentrations of DS-SILY20 also
resulted in the reduction of both IFN-γ and TNF-α. Interestingly,
the treatment of quiescent cultures with low concentrations of
DS-SILY20 caused an increase of IL-1β and IL-6. This observed
increase in IL-1β and IL-6 corresponds with a slight increase in
quiescent SMC migration that was also observed in this work,
indicating that low concentrations of the compound stimulates a
small level of smooth muscle cell repair and remodeling[43].
In addition to the effect of DS-SILY20 on SMC cytokine
production, the antithrombotic therapeutic influences cellular
expression of thrombomodulin, a transmembrane glycoprotein,
which plays an important role in maintaining vascular
thromboresistance. During the coagulation cascade,
thrombomodulin forms a complex with thrombin, allowing for
the activation of protein C and thus, indirectly increasing
fibrinolysis and inhibiting blood coagulation[44]. Similar to
previous reports, thrombomodulin levels were almost
indiscernible in quiescent SMC cultures[45]. A decrease in
thrombomodulin production was exhibited in proliferative SMC
cultures with low concentrations of DS-SILY. While this
response is not ideal, the concerns associated with decreased
thrombomodulin expression may be overshadowed by the
ability of DS-SILY20 to reduce other attributes associated with
proliferative SMCs, as demonstrated in both the in vitro and in
vivo studies within this work. However, we also demonstrate
that the expression of thrombomodulin increases in proliferative
SMCs treated with 1 or 10 μM DS-SILY20. As it has previously
been determined that the overexpression of thrombomodulin,
or similarly, the systemic administration of thrombomodulin,
reduces inflammatory cell infiltration and neointimal formation
in several animal models[46,47], the ability of DS-SILY20 to
upregulate thrombomodulin in proliferative, unhealthy SMCs
may serve as another important mechanism in the prevention
of restenosis. This suggests that higher treatment
concentrations of DS-SILY (~10 μM) are warranted.
An in vivo proof-of-principle was evaluated in Ossabaw
miniature pigs in an effort to further assess the ability of DS-
SILY20 to inhibit intimal hyperplasia. Previously, we have
demonstrated the ability of DS-SILY to specifically bind to type-
I collagen, serving as a barrier to platelet adhesion and
activation in vitro[30]. Here we further examined the ability of
DS-SILY20 to block platelet adhesion and activation in vivo
using an Ossabaw miniature pig model. Following balloon
angioplasty-induced denudation of the endothelium, solutions
of 10 μM DS-SILY20 or the sham control were delivered to the
injured arterial wall via porous balloon catheter. Short-term
effects on platelet activation were examined. Examination of
denuded artery walls indicated that platelets were scarcely
visible on DS-SILY20 treated vessels, while significant platelet
coverage was visualized on saline-treated arteries. More
interestingly, platelets attached to saline-treated arteries show
numerous projections and spreading of platelets, which is
indicative of platelet activation[48]. However, platelets on DS-
SILY20 treated artery walls maintain a largely rounded
morphology signifying inhibition of platelet activation. These
findings demonstrate that in vivo delivery of DS-SILY20 is
achievable and indicate efficacy of inhibited platelet activation
on the endothelium-denuded artery wall.
Furthermore, to examine the effects of DS-SILY20 on
reducing neointimal hyperplasia, artery histology was assessed
after a 1-month recovery following balloon angioplasty in
stented and non-stented arteries. Intimal hyperplasia was
significantly reduced in vessels treated with DS-SILY20
compared to sham controls. Based on the ability of DS-SILY20
to inhibit SMC proliferation, migration, and protein synthesis in
vitro, it is possible that DS-SILY20 prevents intimal hyperplasia
through multiple mechanisms culminating in the direct
suppression of the cellular behavior that is stimulated by direct
mechanical injury of the blood vessel during balloon expansion.
As DS-SILY also binds to the luminal surface of the injured
artery and inhibits platelet binding and activation, it is also likely
that DS-SILY indirectly prevents hyperplasia through an
antithrombotic mode of action, as shown in our previous
work[30]. Interestingly, a significant reduction in intimal
hyperplasia was observed in both stented and non-stented
vessels, indicating the delivery of DS-SILY20 from balloon
catheters alone, without additional stent implantation, may
alone provide medically significant vessel healing.
In conclusion, DS-SILY demonstrates multiple biological
activities that may all synergistically contribute to an improved
treatment paradigm for balloon angioplasty. DS-SILY20 directly
inhibited platelet binding and activation on denuded arteries in
vivo. In addition, in vitro the therapeutic was shown to stimulate
thrombomodulin production in proliferative SMCs, thus
potentially contributing to the antithrombotic potential of DS-
SILY in vivo. The decorin mimic also suppressed SMC
proliferation, migration, and protein synthesis in proliferative
SMC cultures in vitro, which may contribute to the inhibition of
intimal hyperplasia seen following DS-SILY treatment after
balloon angioplasty in vivo. Finally, DS-SILY20 suppressed
SMC pro-inflammatory cytokine production in vitro, which may
also prove critical in its ability to inhibit intimal hyperplasia in
vivo. Future studies are aimed at better elucidating the
mechanisms through which these multiple activities contribute
to improved vessel healing following PCI in vivo.
Supporting Information
Figure S1.  Schematic Representation of Fluorescently
Labeled Protein. (A) Following incubation with DS-SILY20,
cultures were doped with L-azidohomoalanine (AHA) in serum-
free media for 4 hrs. Cells were then rinsed in PBS and
incubated in co-culture media overnight to allow protein
production. (B) Cultures were fixed and permeabilized, prior to
the selective conjugation of Alexa Fluor 594 (AF-594) via
copper-catalyzed azide-alkyne ligation. De novo protein
synthesis was then visualized by detecting fluorescent tag
attached directly to the unnatural amino acid.
(TIF)
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